Program
glofitamab
Also written as “Glofitamab” and “IV Glofitamab”.
Its studies are mostly in Lymphoma · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell, led by Hoffmann-La Roche.
Furthest: phase 3, since May 26, 202013 company-led studies, 9 open or runningNext primary completion: Mar 22, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 139 open or running | phase 3since May 26, 2020 | Mar 7, 2017 | Mar 22, 2027phase 1 · NCT06624085 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 7, 2017First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT03075696 · 940 enrolled · United States, Australia, Belgium and more
- Mar 17, 2020Phase 1 study in Lymphoma, B-CellNCT04313608 · 23 enrolled · Australia
- May 26, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04408638 · 270 enrolled · United States, Australia, Belgium and more
- Dec 1, 2020Phase 1 study in LymphomaNCT04657302 · 30 enrolled · China
- Jul 19, 2021Phase 2 study in LymphomaNCT04980222 · 46 enrolled · United States, Denmark, France and more
- Nov 23, 2021Phase 1 study in Lymphoma, Non-HodgkinNCT05219513 · 53 enrolled · United States, Australia, Denmark and more
- Dec 13, 2021Phase 1 study in Lymphoma, Non-HodgkinNCT05169515 · 121 enrolled · United States, Israel, Italy and more
- May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05364424 · 43 enrolled · United States
- Sep 6, 2022Phase 2 study in RecurrenceNCT05533775 · 65 planned · United States, Australia, Brazil and more
- Sep 14, 20232 phase 3 studiesNCT06084936, NCT06047080
- Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico
- Jan 21, 2025Phase 2 study in RecurrenceNCT06806033 · 130 planned · United States, Australia, Canada and more
- Nov 10, 2026Primary completion moved from 2027-01-31 to 2029-07-31Date moved laterphase 2 · +30 months · NCT06806033
Ahead
- Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085
- Aug 31, 2027Primary completion: phase 3 study in LymphomaNCT06084936
- Oct 1, 2027Primary completion: phase 3 study in Large B-Cell LymphomaNCT06047080
- Mar 31, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04408638
TargetBeta
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 3 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06806033Recurrence · United States, Australia, Canada and more | 2 | Recruiting | Jul 31, 2029 | 130 |
| NCT06624085Lymphoma · United States, Puerto Rico | 1 | Active, not recruiting | Mar 22, 2027 | 50 |
| NCT06084936Lymphoma · United States, Australia, Brazil and more | 3 | Recruiting | Aug 31, 2027 | 182 |
| NCT06047080Large B-Cell Lymphoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 1, 2027 | 1,130 |
| NCT05533775Recurrence · United States, Australia, Brazil and more | 2 | Recruiting | Nov 30, 2029 | 65 |
| NCT05364424Lymphoma, Large B-Cell, Diffuse · United States | 1 | Completed | Oct 15, 2025 | 43 |
| NCT05169515Lymphoma, Non-Hodgkin · United States, Israel, Italy and more | 1 | Active, not recruiting | Apr 30, 2029 | 121 |
| NCT05219513Lymphoma, Non-Hodgkin · United States, Australia, Denmark and more | 1 | Terminated | Jul 17, 2024 | 53 |
| NCT04980222Lymphoma · United States, Denmark, France and more | 2 | Active, not recruiting | Oct 24, 2024 | 46 |
| NCT04657302Lymphoma · China | 1 | Completed | Oct 25, 2022 | 30 |
| NCT04408638Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more | 3 | Active, not recruiting | Mar 31, 2028 | 270 |
| NCT04313608Lymphoma, B-Cell · Australia | 1 | Completed | Oct 26, 2021 | 23 |
| NCT03075696Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 30, 2029 | 940 |
How it is read
Names in the registry
- “Glofitamab”, 12 entries
- “IV Glofitamab”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, 4 studies
- Lymphoma, Non-Hodgkin, 3 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
- Lymphoma, B-Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.